A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration

• Status: Completed
• Trial end date: 2003-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine the concentration of anecortave acetate (15 or 30 mg versus placebo) that is safe and effective for the inhibition of the growth of blood vessels in the retina in patients with wet AMD.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Anecortave; Hydrocortisone

Criteria

Inclusion Criteria:

• Ages 50 years and over

• Other protocol-defined inclusion and exclusion criteria may apply.